

MedGenome announces free access to OncoPeptTOPE™, its proprietary database of neo-antigens and neo-epitopes

OncoPeptTOPE™ is freely accessible online to DNA / Peptide vaccine researchers



FOSTER CITY, CA, UNITED STATES,
April 29, 2016 /EINPresswire.com/ --

MedGenome recently announced that its proprietary OncoPeptTOPE™ database of neo-antigens and neo-epitopes derived from genetic alterations using TCGA data will be made freely accessible to researchers in the cancer immunotherapy space. The database captures CD4+/CD8+ T-cell neo-epitopes from neo-antigens based on their binding affinity to different HLA types selected based on their expression in cancer cells. The mutated genes are also rank ordered according to their T-cell neo-epitope burden.

The database tool can be accessed online at <http://oncotope.medgenome.com/>. The database has been developed utilizing MedGenome's proprietary pipeline for neo-antigen and neo-epitope identification and prioritization applied against the catalogue of genetic mutations in cancer. The pipeline is also available via the [OncoPeptVAC™](#) service at MedGenome to customers that are focusing on DNA / peptide vaccine development.

MedGenome envisions that access to the OncoPeptTOPE™ database will save a significant amount of analysis time for researchers involved in DNA/Peptide vaccine composition, structure and validations - across discovery, pre-clinical and clinical stages.

About MedGenome

MedGenome (<http://www.medgenome.com>) is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Its unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized health care. MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of [genomics research services](#) globally.

Forward-looking Statements:

This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of

the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Hiranjith GH
MedGenome
7022020883
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.